1762177441 unnamed file.jpg

Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger

Kimberly-Clark is set to acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at approximately $48.7 billion, creating one of the world’s largest consumer health goods companies, AP reported.Under the terms of the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. Based…

Read More
1758642972 unnamed file.jpg

Kenvue stock rebounds: Tylenol maker rises 6% after Donald Trump’s autism claims; analysts see limited legal impact

Shares of Tylenol maker Kenvue rebounded sharply on Tuesday, recovering from a steep fall triggered by President Donald Trump’s unfounded remarks linking the drug to autism.At the opening bell, Kenvue shares climbed more than 6 per cent, a day after plunging 7.5 per cent, AP reported. Trump had repeatedly instructed pregnant women to avoid Tylenol…

Read More